[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561633":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":59,"collaborators":61,"id":64,"slug":19,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":19,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":19,"overallStatus":49,"whyStopped":19,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Rennes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient","EXPERIMENTAL","repeated allogenic ASCs IT injections",[13],"Drug: Adipose tissue-derived Mesenchymal Stromal Cells",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Adipose tissue-derived Mesenchymal Stromal Cells",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Laure MICHEL, Pr","PRINCIPAL_INVESTIGATOR",[25,30],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","0299284321","+33","laure.michel@chu-rennes.fr",{"name":31,"role":26,"phone":32,"phoneExt":28,"email":33},"Marie-Laure GERVAIS, PhD","0299282555","marie-laure.gervais@chu-rennes.fr",[35,47],{"facility":36,"status":37,"city":38,"state":19,"zip":19,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":19},"APHP Henri Mondor","ACTIVE_NOT_RECRUITING","Créteil","France","FR",{"type":42,"coordinates":43},"Point",[44,45],2.46569,48.79266,{"lat":45,"lon":44},{"facility":48,"status":49,"city":50,"state":19,"zip":19,"country":39,"countryCode":40,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"CHU Rennes","RECRUITING","Rennes",{"type":42,"coordinates":52},[53,54],-1.67431,48.11109,{"lat":54,"lon":53},[57,58],{"name":22,"role":26,"phone":19,"phoneExt":19,"email":19},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":60,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[62],{"name":63,"class":6},"Etablissement Français du Sang","100561633",false,"NCT06592703","Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis","Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis: an Open-label Phase I Clinical Trial.","MAESTRO-4MS","Inclusion Criteria:\n\n* Patient with Primary Progressive MS according to the criteria of Mc Donald 2017 (Thompson et al Lancet neurol, 2017)\n* Age between 18 and 55 years\n* EDSS score: 3 to 6 at inclusion\n* Documented evidence of disability progression independent of relapse activity at any point in time over the 2 years prior to the screening visit\n* Positive CSF with oligoclonal bands\n* For women of childbearing potential (WOCBP), effective contraception as per the CFTG recommendations (version 1.1)\n* Having signed a free, informed and written consent\n* Affiliated to social security scheme\n\nExclusion Criteria:\n\n* Inflammatory activity during the past year (relapses or new T2 MRI lesions)\n* Disease Modifying Drugs during the past year\n* Treatment with high dose corticosteroids during the 30 days preceding the inclusion\n* Contra indication to lumbar puncture\u002Fintrathecal infusion: intracranial hypertension, puncture site infections, severe thrombocytopenia (\\\u003C50 G\u002FL), anticoagulant or fibrinolytic treatment\n* Participation in another therapeutic trial in the last 6 months\n* Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breastfeeding women, minors, persons unable to express their consent","ALL","18 Years","55 Years",{"count":75,"type":76},10,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","In this study, we propose, for the first time, to test the safety and the potential efficacy of repeated allogenic Adipose tissue-derived Mesenchymal Stromal Cells IT injections in Primary Progressive Multiple Sclerosis patients.",[82],"Multiple Sclerosis","2025-12-31",{"date":85,"type":86},"2026-01-05","ACTUAL",{"date":88,"type":86},"2025-03-06",{"date":90,"type":76},"2029-12",{"name":5,"class":6},2]